PRESS RELEASE
Innexus Nutraceuticals will be at Vitafoods Europe 2019 – find them on their new distributor IMCD’s stand H64
Netherlands-based Innexus Nutraceuticals will be present at the booth of its new distributor, IMCD, at Vitafoods Europe 2019. Exhibiting on Stand H64, Innexus will showcase OptiPEA®, the natural pain relief solution.
The strategic partnership will be more widely available to European supplement manufacturers (Scandinavian countries excluded). With demand rising for alternatives to pain relief drugs, OptiPEA® is a safe and reliable nutraceutical solution. It is palmitoylethanolamide (PEA), a naturally occurring bioactive lipid which has consistently been shown to deliver positive results without negative side effects.
OptiPEA® is produced sustainably from RSPO-certified palmitic acid and manufactured entirely in Europe using a patented GMP production process. It is an excellent alternative to Cannabidiol (CBD), which has recently been classified by the EU as a ‘novel food’, creating uncertainty around its status in the supplements sector. OptiPEA® is also a better alternative to CBD because it is a single molecule and therefore much easier to measure into precise doses. In addition, it has a consistent quality and its origin is completely, transparent and sustainable.
Samuel Zonneveld, CEO at Netherlands-based Innexus, said: “Teaming up with IMCD is a golden combination. The availability of IMCD’s sales capacity, technical support and distribution network will be the next big step for OptiPEA®. Choosing IMCD over other distributors was an easy choice for us as IMCD has a clear vision and method of adding extra value to OptiPEA®.”
Cameron Richardson, IMCD Nutraceuticals Market Manager commented: “Selecting innovative specialty ingredients is at the core of IMCD’s strategy, and that is why we are very pleased to add OptiPEA® to our portfolio. Innexus Nutraceuticals has taken extra steps to develop a PEA product with unique features. When everyone else was focusing on CBD, we had a clear vision for OptiPEA® as a viable alternative from a scientific and regulatory perspective.”
ENDS
For more information contact:
Alistair Pulling, Ingredient Communications
Email: alistair@ingredientcommunications.com
Tel: +44 1293 886291 | +44 7507 277733
About palmitoylethanolamide
Fatty acid amides like palmitoylethanolamide (PEA) are vital to many chemical signalling processes in the body. They are produced when we need to ease pain and inflammation, helping to return various kinds of body cells to a normal, healthy state of functioning. Under normal circumstances enough PEA can be produced in almost every cell by on-demand synthesis. When out of balance, however, the body may not be able to synthesize adequate levels. Taking PEA as a dietary supplement increases the amount of palmitoylethanolamide wherever shortages occur, thus restoring balance to biological processes. PEA’s benefits are widespread, as it affects almost all familiar receptors of the endocannabinoid system. In addition, it binds to the nuclear PPAR-alpha receptor. In case of chronic pain and inflammation, the body simply cannot make enough PEA, which is when supplementation can help.
The use of PEA is supported by more than 700 scientific articles, 60 medical indications for use, and 60 years of research, PEA is a natural compound that delivers compelling pain relief benefits. The pain killing and anti-inflammatory properties of PEA have been known for decades but they were initially poorly understood. During the 1990s Italian Nobel Prize laureate Dr. Rita Levi-Montalcini caused renewed worldwide attention among researchers when she showed for the first time that PEA may control overactive inflammatory cells in many diseases. This insight was the engine behind PEA’s clinical revival over the past decades.